COMBINATION LIPID-LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS (CASE SERIES FROM CLINICAL PRACTICE)
https://doi.org/10.17802/2306-1278-2026-15-2-138-148
Abstract
Highlights
- Combined lipid–lowering therapy, including rosuvastatin and ezetimibe (the true fixed combination is ZENON®), has been proven effective and safe in the prevention of cardiovascular complications in patients with atherosclerotic pathology, including after acute cardiovascular disasters, with diabetes mellitus and the elderly.
- There are few data on the experience of using combined lipid-lowering therapy (statin and ezetimibe) in patients with aortic stenosis, which actualizes the demonstration of cases from real clinical practice in publications.
Abstract
This article presents our clinical experience and reviews existing clinical studies evaluating the efficacy and safety of combination lipid-lowering therapy with a statin and a cholesterol absorption inhibitor (ezetimibe) for the prevention of cardiovascular complications associated with atherosclerosis. Clinical examples of outpatient management of patients with atherosclerosis and concomitant cardiovascular diseases using a fixed-dose combination of rosuvastatin at the maximum tolerated dose and ezetimibe (ZENON®) are presented. These results demonstrated positive results in terms of cardiovascular complication prevention over a 9-month follow-up period, achievement of target lipid profile values, and good tolerability of this combination.
Supporting agencies: The clinical cases presented are based on the activities of the regional lipid center at the State Budgetary Healthcare Institution of the Kemerovo Region «Kuzbass Clinical Cardiology Dispensary named academician L.S. Barbarash» and the results of the exploratory scientific study № 2026-0002 of the Research Institute of Cardiovascular Surgery and Cardiovascular Diseases «Innovative models for assessment, prevention and correction of cardiovascular risk based on the study of psychological factors and comorbidity of somatic pathologies in patients with diseases of the circulatory system» (№ 419_9 «Effects of using PCSK9-targeted therapy in patients with degenerative aortic valve stenosis to slow down disease progression»).
About the Authors
Vasiliy V. Kashtalap
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
Professor of the RAS, PhD, MD, Professor, Head of the Department of Clinical Cardiology, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Daria Yu. Sedykh
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
PhD, Senior Researcher, Laboratory of Circulatory Pathology, Department of Clinical Cardiology, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Ekaterina Albertovna Pavlova
State Budgetary Healthcare Institution of the Kemerovo region “Kuzbass Clinical Cardiology Dispensary named after Academician L.S. Barbarash”
Russian Federation
Russian Federation
Lipidologist of the Cardiological Polyclinic, State Budgetary Healthcare Institution of the Kemerovo region “Kuzbass Clinical Cardiology Dispensary named after Academician L.S. Barbarash”, Kemerovo, Russian Federation
References
1. Ignatyeva V.I., Ezhov M.V., Kontsevaya A.V., et al. Socioeconomic damage caused by elevated levels of low-density lipoprotein cholesterol. Medical Technologies. Assessment and Choice. 2025; 47 (2): 88-98. (In Russ.) doi:10.17116/medtech20254702188.
2. Drapkina O.M., Imaeva A.E., Kutsenko V.A., et al. Dyslipidemias in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023; 22 (8S): 3791. (In Russ.) doi:10.15829/1728-8800-2023-3791.
3. Polyakova E.A., Khalimov Y.S., Bazhenova E.A., et al. Lipoprotein(a), atherosclerosis, and cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2024; 20 (5): 559-565. (In Russ.) doi:10.20996/1819-6446-2024-3080.
4. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., et al. Lipid metabolism disorders. Clinical guidelines 2023. Russian Journal of Cardiology. 2023; 28 (5): 5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.
5. Boytsov S.A., Drapkina O.M., Shlyakhto E.V., et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021; 20 (5): 3007. (In Russ.) doi:10.15829/1728-8800-2021-3007.
6. Song Y., Liu J., Zhao K., et al. Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. Cell Metab. 2021; 33 (10): 1911-1925. doi10.1016/j.cmet.2021.09.001.
7. Fernández-Friera L., Fuster V., López-Melgar B., et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol. 2017; 70 (24): 2979-2991. doi10.1016/j.jacc.2017.10.024.
8. Newman C.B., Preiss D., Tobert J.A., et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019; 39 (2): e38-e81. doi:10.1161/ATV.0000000000000073.
9. Khan S.U., Yedlapati S.H., Lone A.N., et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022; 377: e069116. doi:10.1136/bmj-2021-069116.
10. Sergienko I.V., Yezhov M.V., Gurevich V.S., et al. Comparative efficacy and safety of statin monotherapy and their combination with ezetimibe. (Results of the Russian retrospective observational study UNISON). Atherosclerosis and dyslipidemia. 2022; 4 (49): 25-38. (In Russ.) doi:10.34687/2219-8202. JAD.2022.04.0003.
11. Leosdottir M., Schubert J., Brandts J., et al. Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry. J Am Coll Cardiol. 2025; 85 (15): 1550-1564. doi10.1016/j.jacc.2025.02.007.
12. Mach F., Koskinas K.C., Roeters van Lennep J.E., et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025; 46 (42): 4359-4378. doi:10.1093/eurheartj/ehaf190.
13. Zhan S., Tang M., Liu F., et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018; 11 (11): CD012502. doi:10.1002/14651858.CD012502.pub2.
14. Sydhom P., Al-Quraishi B., El-Shawaf M., et al. The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024; 24 (1): 660. doi:10.1186/s12872-024-04144-y.
15. Ah Y.M., Jeong M., Choi H.D. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. PLoS One. 2022; 17 (3): e0264437. doi:10.1371/journal.pone.0264437.
16. Oyama K., Giugliano R.P., Blazing M.A., et al. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021; 78 (15): 1499-1507. doi:10.1016/j.jacc.2021.08.011.
17. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372 (25): 2387-97. doi:10.1056/NEJMoa1410489.
18. Fei Y., Guyatt G.H., Alexander P.E., et al. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval Clin Pract. 2018; 24 (1): 222-231. doi:10.1111/jep.12663.
19. Rossebø A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359 (13): 1343-56. doi:10.1056/NEJMoa0804602.
20. Desai M.Y., Braunwald E. The Pathophysiologic Basis and Management of Calcific Aortic Valve Stenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2025; 86 (9): 659-672. doi:10.1016/j.jacc.2025.06.049.
21. Capoulade R., Clavel M.A., Dumesnil J.G., et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. J Am Coll Cardiol. 2012; 60 (3): 216-23. doi:10.1016/j.jacc.2012.03.052.
22. Greve A.M., Bang C.N., Boman K., et al. Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis. Am J Cardiol. 2019; 124 (11):1736-1740. doi:10.1016/j.amjcard.2019.08.037.
23. Small A.M., Yutzey K.E., Binstadt B.A., et al. Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association. Circulation. 2024; 150 (6):e109-e128. doi:10.1161/CIR.0000000000001254.
24. Sengupta P.P., Kluin J., Lee S.P., et al. The future of valvular heart disease assessment and therapy. Lancet. 2024; 403 (10436): 1590-1602. doi:10.1016/S0140-6736(23)02754-X.
25. Lindman B.R., Sukul D., Dweck M.R., et al. Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 78 (23): 2354-2376. doi:10.1016/j.jacc.2021.09.1367.
26. Otto C.M., Newby D.E., Hillis G.S. Calcific Aortic Stenosis: A Review. JAMA. 2024; 332 (23): 2014-2026. doi:10.1001/jama.2024.16477.
27. Thiago L., Tsuji S.R., Nyong J., et al. Statins for aortic valve stenosis. Cochrane Database Syst Rev. 2016; 9 (9): CD009571. doi:10.1002/14651858.CD009571.pub2.
28. Kim B.K., Hong S.J., Lee Y.J., et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; 400 (10349): 380-390. doi:10.1016/S0140-6736(22)00916-3.
29. Soleimani H., Mousavi A., Shojaei S., et al. Safety and Effectiveness of High-Intensity Statins Versus Low/Moderate-Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL-C Goals: A Systematic Review and Meta-Analysis. Clin Cardiol. 2024; 47 (8): e24334. doi:10.1002/clc.24334.
30. Kelly F.A., de Moraes F.C.A., Lôbo A.O.M., et al. Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: A meta-analysis. J Clin Lipidol. 2024; 18 (6): e893-e904. doi:10.1016/j.jacl.2024.07.013.
31. Kashani A., Sallam T., Bheemreddy S., et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008; 101 (11): 1606-13. doi: 10.1016/j.amjcard.2008.01.041.
32. Luo L., Yuan X., Huang W., et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern Med J. 2015; 45 (5): 546-57. doi:10.1111/imj.12706.
Review
For citations:
Kashtalap V.V., Sedykh D.Yu., Pavlova E.A. COMBINATION LIPID-LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS (CASE SERIES FROM CLINICAL PRACTICE). Complex Issues of Cardiovascular Diseases. 2026;15(2):138-148. (In Russ.) https://doi.org/10.17802/2306-1278-2026-15-2-138-148
Views:
213
JATS XML
